Replication‐Deficient Rabies Virus–Based Vaccines Are Safe and Immunogenic in Mice and Nonhuman Primates
- 15 October 2009
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 200 (8), 1251-1260
- https://doi.org/10.1086/605949
Abstract
Although current postexposure prophylaxis rabies virus (RV) vaccines are effective, approximately 40,000-70,000 rabies-related deaths are reported annually worldwide. The development of effective formulations requiring only 1-2 applications would significantly reduce mortality. We assessed in mice and nonhuman primates the efficacy of replication-deficient RV vaccine vectors that lack either the matrix (M) or phosphoprotein (P) gene. A single dose of M gene-deficient RV induced a more rapid and efficient anti-RV response than did P gene-deficient RV immunization. Furthermore, the M gene-deleted RV vaccine induced 4-fold higher virus-neutralizing antibody (VNA) levels in rhesus macaques than did a commercial vaccine within 10 days after inoculation, and at 180 days after immunization rhesus macaques remained healthy and had higher-avidity antibodies, higher VNA titers, and a more potent antibody response typical of a type 1 T helper response than did animals immunized with a commercial vaccine. The data presented in this article suggest that the M gene-deleted RV vaccine is safe and effective and holds the potential of replacing current pre- and postexposure RV vaccines.Keywords
This publication has 31 references indexed in Scilit:
- Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein geneVaccine, 2008
- Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoproteinVeterinary Microbiology, 2002
- One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccinationVaccine, 2001
- Higher production of rabies virus in serum-free medium cell cultures on microcarriersJournal of Biotechnology, 2001
- Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine VectorJournal of Virology, 2001
- Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administrationJournal of General Virology, 2001
- Enhanced Avidity Maturation of Antibody to Human Immunodeficiency Virus Envelope: DNA Vaccination with gp120–C3d Fusion ProteinsAIDS Research and Human Retroviruses, 2001
- Post-exposure DNA vaccination protects mice against rabies virusVaccine, 2001
- Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccinesVaccine, 2000
- Recombinant rabies virus as potential live-viral vaccines for HIV-1Proceedings of the National Academy of Sciences of the United States of America, 2000